Heparins and low-molecular-weight heparins

Heparins are injected anticoagulants. Low-molecular-weight heparins are fractions of heparin, and MeSH calls them effective antithrombotic agents. A US label for premixed heparin lists preventing and treating venous thrombosis and pulmonary embolism among its uses. This is the class page.

Also called Unfractionated Heparin · Low-molecular-weight heparins · LMWH

  • Drug
  • In this atlas

Overview

Technical summary

Class page. MeSH headings D006493 (Heparin) and D006495 (Heparin, Low-Molecular-Weight) are both broad matches: the first is one substance and the second is one half of this class. The scope note of the second says the fractions weigh usually between 4000 and 6000 kD. A US label for premixed heparin sodium says heparin inhibits the reactions that lead to blood clotting and fibrin clots, and lists prophylaxis and treatment of venous thrombosis and pulmonary embolism first among its uses. A US label for one low molecular weight heparin product describes it as a low molecular weight heparin and carries a boxed warning on epidural or spinal hematomas. Statements are scoped to each product. No trial result and no dose is recorded here.

Trials at a glance

The figures count the 13 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
13
Phase 3 or 4
11
Recruiting
0
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseCompletedTerminatedUnknown statusAll statuses
Phase 21001
Phase 32013
Phase 45128
No phase1001
All phases91313

Conditions these trials study

And 4 more.

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

And 8 more.

Drugs in this class

1 drug in this atlas is filed under Heparins and low-molecular-weight heparins, with the registry trials and FDA regulatory decisions this atlas holds for each. With Heparins and low-molecular-weight heparins itself, the class has 24 distinct trials and 35 distinct FDA decisions; a trial or decision that two of them share counts once there.

  • Heparin 16 trials, 35 FDA decisions

About this drug

Level
Class
Mechanism
Heparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots (US drug label for premixed heparin sodium).

Classification codes

  • MeSH id.nlm.nih.gov linked data, retrieved 2026-11-09 D006493
  • MeSH id.nlm.nih.gov linked data, retrieved 2026-11-09 D006495

Claims and evidence

No claims are published for this drug yet.

Registry records

Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry trials 13

Record details

Record id
cardio:heparins-and-low-molecular-weight-heparins
Content hash
576148c6e940d60e8248663c4e1539c7bd78cbac3fd1b9f7cb4db18da8e884c9